The effect of azithromycin and Chlamydophilia pneumonia infection on expansion of small abdominal aortic aneurysms - A prospective randomized double-blind trial

Journal of Vascular Surgery

Volumn 50, Issue 1, 2009, Pages 23-29

  Karlsson, Lars ^a,d   Gnarpe, Judy ^b   Bergqvist, David ^a   Lindbäck, Johan ^c   Pärsson, Håkan ^a,e  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Centre of Clinical Research   (Sweden)

^d GÄVLE HOSPITAL   (Sweden)

^e HELSINGBORG HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZITHROMAX; AZITHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; AGED; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHLAMYDIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOFLUORESCENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; TREATMENT DURATION;

AGED; ANTI-BACTERIAL AGENTS; AORTIC ANEURYSM, ABDOMINAL; AZITHROMYCIN; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; PROSPECTIVE STUDIES;

EID: 67649203188     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2008.12.048     Document Type: Article

References (37)

1. Wills A., Thompson M.M., Crowther M., Sayers R.D., and Bell P.R. Pathogenesis of abdominal aortic aneurysms - cellular and biochemical mechanisms. Eur J Vasc Endovasc Surg 12 (1996) 391-400
2. Vine N., and Powell J.T. Metalloproteinases in degenerative aortic disease. Clin Sci (Lond) 81 (1991) 233-239
3. Kuo C.C., Grayston J.T., Campbell Y.A., Goo R., Wissler W., and Benditt E.P. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci USA 92 (1995) 6911-6914
4. Juvonen J., Juvonen T., Laurila A., Alakärppä H., Lounatmaa K., Surcel H.M., et al. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 25 (1997) 499-505
5. Karlsson L., Gnarpe J., Nääs J., Olsson G., Lindholm J., Steen B., and Gnarpe H. Detection of viable Chlamydia pneumoniae in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 19 (2000) 630-635
6. Vink A., Poppen M., Schoneveld A.H., Roholl P.J., de Kleijn D.P., Borst C., and Pasterkamp G. Distribution of Chlamydia pneumoniae in the human arterial system and its relation to the local amount of atherosclerosis within the individual. Circulation 103 (2001) 1613-1617
7. Tomasi T.B., and Grey H.M. Structure and function of immunoglobulin A. Prog Allergy 16 (1972) 181-213
8. Falck G., Gnarpe J., and Gnarpe H. Persistent Chlamydia pneumoniae infection in a Swedish family. Scand J Infect Dis 28 (1996) 271-273
9. Lindholt J.S., Ashton H.A., and Scott R.A. Indicators of infection with Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysms. J Vasc Surg 34 (2001) 212-215
10. Fong I.W., Chiu B., Viira E., Jang D., Fong M.W., Peeling R., and Mahony J.B. Can an antibiotic (macrolide) prevent Chlamydia pneumoniae- induced atherosclerosis in a rabbit model?. Clin Diagn Lab Immunol 6 (1999) 891-894
11. Tambiah J., and Powell J.T. Chlamydia pneumoniae antigens facilitate experimental aortic dilatation: prevention with azithromycin. J Vasc Surg 36 (2002) 1011-1017
12. Mosorin M., Juvonen J., Biancari F., Satta J., Surcel H.M., Leinonen M., Saikku P., and Juvonen T. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 34 (2001) 606-610
13. Vammen S., Lindholt J.S., Ostergaard L., Fasting H., and Henneberg E.W. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 88 (2001) 1066-1072
14. Tiran A., Gruber H.J., Grainer W.F., Wagner A.H., Van Leeuwen E.B., and Tiran B. Aspirin inhibits Chlamydia pneumoniae-induced nuclear factor-kappa B activation, cytokine expression, and bacterial development in human endothelial cells. Arterioscler Thromb Vasc Biol 22 (2002) 1075-1080
15. Kalyanasundaram A., Elmore J.R., Manazer J.R., Golden A., Franklin D.P., et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 43 (2006) 117-124
16. Gnarpe J., Sparr A., Nääs J., and Lundbäck A. Serological analysis of specific IgA to Chlamydia pneumoniae: increased sensitivity of IgA antibody detection using prolonged incubation and high antigen concentration. APMIS 108 (2000) 357-362
17. Gnarpe J., Nääs J., and Lundbäck A. Comparison of a new commercial EIA kit and the microimmunofluorescence technique for determination of IgG and IgA antibodies to Chlamydia pneumoniae. APMIS 108 (2000) 819-824
18. R Development Core Team (2008). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.
19. Tambiah J., Franklin I.J., Trendell-Smith N., Peston D., and Powell J.T. Provocation of experimental aortic inflammation and dilatation by inflammatory mediators and Chlamydia pneumoniae. Br J Surg 88 (2001) 935-940
20. Contopoulos-Ioannidis D.G., Ioannidis J.P., Chew P., and Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 48 (2001) 691-703
21. Parchure N., Zouridakis E.G., and Kaski J.C. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation 105 (2002) 1298-1303
22. Grayston J.T., Campbell L.A., Kuo C.C., Mordhorst C.H., Saikku P., Thom D., and Wang S.P. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 161 (1990) 618-625
23. Gaydos C.A., Summersgill J.T., Sahney N.N., Ramirez J.A., and Quinn T.C. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 64 (1996) 1614-1620
24. Schett G., Xu Q., Amberger A., Van der Zee R., Recheis H., Willeit J., and Wick G. Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. J Clin Invest 96 (1995) 2569-2577
25. Wiedeman J.A., Kaul R., Heuer L.S., Thao N.N., Pinkerton K.E., and Wenman W.M. Tobacco smoke induces persistent infection of Chlamydia pneumoniae in HEp-2 cells. Microb Pathog 37 (2004) 141-148
26. Gieffers J., Rupp J., Gebert A., Solbach W., and Klinger M. First-choice antibiotics at subinhibitory concentrations induce persistence of Chlamydia pneumoniae. Antimicrob Agents Chemother 48 (2004) 1402-1405
27. Lederle F.A., Nelson D.B., and Joseph A.M. Smokers' relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review. J Vasc Surg 38 (2003) 329-334
28. MacSweeney S.T., Ellis M., Worrell P.C., Greenhalgh R.M., and Powell J.T. Smoking and growth rate of small aortic aneurysms. Lancet 344 (1994) 651-652
29. The UK Small Aneurysm Trial Participants. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet 352 (1998) 1649-1655
30. Brady A.R., Thompson S.G., Fowkes F.G., Greenhalgh R.M., Powell J.T., and The UK Small Aneurysm Trial Participants. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 110 (2004) 16-21
31. Lindholt J.S., Heegaard N.H., Vammen S., Fasting H., Henneberg E.W., and Heickendorff L. Smoking, but not lipids, lipoprotein(a) and antibodies against oxidised LDL, is correlated to the expansion of abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 21 (2001) 51-56
32. Sukhija R., Aronow W.S., Yalamanchili K., Sinha N., and Babu S. Prevalence of coronary artery disease, lower extremity peripheral arterial disease, and cerebrovascular disease in 110 men with an abdominal aortic aneurysm. Am J Cardiol 94 (2004) 1358-1359
33. Schlösser F.J., Tangelder M.J., Verhagen H.J., van der Heijden G.J., Muhs B.E., van der Graaf Y., Moll F.L., and SMART study group. J Vasc Surg 47 (2008) 1127-1133
34. Schouten O., van Laanen J.H., Boersma E., Vidakovic R., Feringa H.H., Dunkelgrün M., et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 32 (2006) 21-26
35. Evans J., Powell J.T., Schwalbe E., Loftus I.M., and Thompson M.M. Simvastatin attenuates the activity of matrix metalloproteinase-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg 34 (2007) 302-303
36. Franklin I.J., Walton L.J., Brown L., Greenhalgh R.M., and Powell J.T. Vascular surgical society of Great Britain and Ireland: non steroidal anti-inflammatory drugs to treat abdominal aortic aneurysm. Br J Surg 86 (1999) 707
37. Fagerberg B., Gnarpe J., Gnarpe H., Agewall S., and Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension. Stroke 30 (1999) 299-305